NLS Pharmaceutics Ltd. Files Interim Financials
Ticker: NCEL · Form: 6-K · Filed: Oct 18, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Oct 18, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financials, interim-report, sec-filing
TL;DR
NLS Pharma dropped its Q2 2024 financials on 10/18. Check the balance sheet!
AI Summary
NLS Pharmaceutics Ltd. filed a 6-K report on October 18, 2024, containing unaudited interim condensed financial statements as of June 30, 2024, and December 31, 2023, for the six-month periods ended June 30, 2024, and 2023. The company is incorporated in Switzerland and its principal executive offices are located in Zurich.
Why It Matters
This filing provides investors with an update on NLS Pharmaceutics' financial performance and position as of mid-2024, crucial for assessing the company's ongoing operations and future prospects.
Risk Assessment
Risk Level: medium — The filing contains unaudited financial statements, which are subject to change and may not represent the full financial picture.
Key Numbers
- 6-K — Filing Type (Report of Foreign Private Issuer)
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- June 30, 2024 (date) — Reporting period end date
- December 31, 2023 (date) — Reporting period end date
- October 18, 2024 (date) — Filing date
- Zurich, Switzerland (location) — Principal executive offices
FAQ
What is the primary purpose of this 6-K filing?
This 6-K filing primarily serves to report NLS Pharmaceutics Ltd.'s unaudited interim condensed financial statements as of June 30, 2024, and December 31, 2023, and for the six-month periods ended June 30, 2024, and 2023.
When was this report filed with the SEC?
This report was filed with the SEC on October 18, 2024.
Where are NLS Pharmaceutics Ltd.'s principal executive offices located?
NLS Pharmaceutics Ltd.'s principal executive offices are located at The Circle 6, 8058 Zurich, Switzerland.
Does NLS Pharmaceutics Ltd. file annual reports under Form 20-F or 40-F?
NLS Pharmaceutics Ltd. files annual reports under cover of Form 20-F, as indicated by the checkmark next to it in the filing.
What is the Commission file number for NLS Pharmaceutics Ltd.?
The Commission file number for NLS Pharmaceutics Ltd. is 001-39957.
Filing Stats: 385 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2024-10-18 16:31:39
Filing Documents
- ea0216876-6k_nlspharma.htm (6-K) — 17KB
- ea021687601ex99-1_nlspharma.htm (EX-99.1) — 372KB
- ea021687601ex99-2_nlspharma.htm (EX-99.2) — 137KB
- 0001213900-24-088969.txt ( ) — 3693KB
- nlsp-20240630.xsd (EX-101.SCH) — 38KB
- nlsp-20240630_cal.xml (EX-101.CAL) — 29KB
- nlsp-20240630_def.xml (EX-101.DEF) — 188KB
- nlsp-20240630_lab.xml (EX-101.LAB) — 352KB
- nlsp-20240630_pre.xml (EX-101.PRE) — 202KB
- ea0216876-6k_nlspharma_htm.xml (XML) — 353KB
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations. 101.INS XBRL Instance Document 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: October 18, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 3